Unlike the conventional cancer treatment methods such as surgery, radiotherapy, and chemotherapy, CAR T cells target tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs) expressed on the surface of their target tumor cells with the delicate specificity granted to them by their antibody fragment-equipped targeting domain in a non-major histocompatibility complex (MHC) manner (1, 2). Here, HLA-C is linked to neoplasm.